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Introduction
There are more than 120 members of
the genus Mycobacterium, which are
diverse in pathogenicity, in vivo adapta-
tion, virulence, response to drugs, and
growth characteristics. Mycobacteria oth-
er than M. tuberculosis complex and M.
leprosy are known as Non-Tuberculous
Mycobacteria (NTM) and are known by
various acronyms. They attracted abrupt
attention only after the AIDS epidemic,
but most of the reports were published
from TB non-endemic countries [1] and
only rarely from TB-endemic countries.
This is probably because the chances of
missing NTM species are higher in TB-
endemic countries, which are poorly
equipped and overburdened with other
diseases (Box 1). The information regard-
ing their true incidence and prevalence in
these countries is scarce [2]. In the absence
of such authentic information, the current
dogma has been that the NTM are of the
least consequence. However, we do not
agree with this myth and wish to present
our viewpoint on this important aspect
and emphasize the need for a fresh look at
this neglected aspect.
Prevalence of NTM Infections
before and after the AIDS
Epidemic
We searched methodological search
terms and phrases such as ‘‘non-tubercu-
lous mycobacteria and AIDS’’ in Medline
records and found that 3,020 articles were
published between 1981 and 2009. Using
the same phrase, only 59 articles were
published between 1900 and 1981, indi-
cating a clear upsurge of NTM disease in
the post-AIDS era. However, most of
these publications were from TB non-
endemic countries [1–5], but not much
significance could be adhered to these
isolations [2]. The disseminated NTM
infection is typically seen when the CD4
+
T lymphocyte number falls below 50 ml.
For this reason, it is argued that in TB-
HIV co-endemic countries, AIDS patients
usually die of tuberculosis or other infec-
tions before their CD4
+ count falls low
enough for NTM to cause a disease (Box 2).
Nevertheless, we feel that besides this
argument, in a majority of the patients,




Some workers also consider that the low
detection rate of NTM is due to diversity
in the environmental and climatic condi-
tions in the HIV-TB-endemic countries,
but this argument is not supported by the
literature [3–5]. In most of the surveys, the
rate of human NTM infections is estimat-
ed by non-specific antibody assays or skin
tests [6]. Hence, these findings may not be
a reliable source of information. The
International Union against Tuberculosis
and Lung Diseases (IUATLD) reviewed
data from 14 countries and found that the
M. avium complex (MAC) was the most
frequently isolated species in all these
countries, which included China, India,
and Korea. While M. fortuitum was the
most frequently encountered species in
Belgium (2.1%), the Czech Republic
(17.5%), Denmark (5.3%), Finland (6.7%),
France (6.5%), Germany (12.2%), Italy
(2.5%), Portugal (16.5%), Spain (10.8%),
Switzerland (17.5%), Turkey (33.9%), and
the United Kingdom (6.0%), undoubtedly,
environment is the main reservoir of
NTM. There is no evidence of human-
to-human or animal-to-human transmis-
sion [6]. Most infections are acquired
either from the water (treated or un-
treated) or soil. MAC and M. fortuitum
are frequently isolated from the drinking
water distribution systems and swimming





The overlapping clinical manifestations
of the diseases caused by M. tuberculosis
make the specific diagnosis of NTM
difficult. Even though fever is less common
in NTM pulmonary disease, most patients
will present in a chest x-ray with sporadic
infiltrations, nodular lesions, and cavities
indistinguishable from pulmonary tuber-
culosis, and disease caused by M. kansasii
in HIV-infected patients often mimics
pulmonary tuberculosis [6,7,8,9]. Mycobac-
terium avium-intracellulare commonly causes
disseminated diseases in AIDS patients.
Other NTM infections also produce
highly non-specific manifestations includ-
ing reactivity to a PPD skin test [6,8].
Further, these manifestations are often
overshadowed by co-morbidities such as
chronic obstructive pulmonary disease
(COPD), cystic fibrosis, defects in the chest
wall, gastroesophageal reflux diseases,
bronchiectasis, aspergilloma, etc. [6]. Al-
beit in pulmonary NTM disease chronic
cough and fatigue are very common, fever
and sweats may be less frequent, unlike
tuberculosis. Malaise, hemoptysis, weight
loss, and wasting are uncommon and
usually indicate advanced disease. NTM
co-infections with M. tuberculosis disease are
not infrequent but are rarely diagnosed
[2]. The NTM infections pose a challenge
for a directly observed treatment–short
course (DOTS) programme because under
Citation: Gopinath K, Singh S (2010) Non-Tuberculous Mycobacteria in TB-Endemic Countries: Are We
Neglecting the Danger? PLoS Negl Trop Dis 4(4): e615. doi:10.1371/journal.pntd.0000615
Editor: Richard O. Phillips, Kwame Nkrumah University of Science and Technology (KNUST) School of Medical
Sciences, Ghana
Published April 27, 2010
Copyright:  2010 Gopinath, Singh. This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
Funding: The authors received no specific funding for this article.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sarman_singh@yahoo.com
www.plosntds.org 1 April 2010 | Volume 4 | Issue 4 | e615this programme the patient is treated only
on the basis of smear findings.
Ethnicity, Occupation, and
Genetic Susceptibility?
In a recent study carried out in Thai-
land [7], it was found that nearly half
(46%) of the disseminated NTM infections
in HIV-negative cases were associated
with farming. The commonest organ
involved was lymph node (89%), followed
by skin and soft tissue (26%). The
agricultural injuries added with exposure
to NTM contaminated soil and water lead
to tissue invasion and disease causation.
Some authors have reported the role of
genetic susceptibility for NTM infections,
such as the multiple mutations in the
interferon-c receptor 1 gene [10] and with
parental consanguinity. However, consan-
guinity is not confined to any particular
ethnic group or geographic region. In one
study Caucasian ethnicity was correlated
with NTM lymphadenitis and non-Cau-
casian ethnicity with tuberculosis [11].
Ethnicity is proposed as the reason for
low prevalence of NTM in TB-endemic
countries by some workers. We, however,
think that it is instead due to the prior
exposure of this population to M. tubercu-
losis, which mounts an adaptive protective
immunity against NTM. Studies have also
shown a vice versa effect, that adaptive
immunity developed by exposure to NTM
can provide cross-protection against TB
and leprosy [12]. Therefore, we feel that
ethnicity is least likely to be the reason for
this underreporting. In our opinion, NTM
are most likely being missed due to lack of
awareness. In India, we were probably the
first to highlight this issue, which is
hesitantly but steadily being appreciated
by others now.
Association of NTM with Other
Diseases
Normally most NTM infections are
asymptomatic, but under certain circum-
stances these mycobacteria can cause a
variety of symptoms, including serious
morbidity and mortality. For instance,
the strongest association of NTM pulmo-
nary infections has been reported with
structural lung disease, such as COPD,
bronchiectasis, cystic fibrosis, pneumoco-
niosis, pulmonary alveolar proteinosis, and
esophageal motility disorders [6]. Though
disseminated NTM infections typically
occur only during severe immune suppres-
sion, in HIV-negative patients disseminat-
ed NTM infections are rare and have been
associated with specific genetic syndromes
such as mutations in interferon (IFN)-c
and interleukin (IL)-12 synthesis and
defects in response pathways including
the signal transducer and activator of
transcription 1 (STAT1) and in the
nuclear factor-kb essential modulator
(NEMO]. Often these genetic defects are
associated with an increased susceptibility
to various opportunistic infections and
hypersensitivity responses. All mycobacte-
ria including the NTM are strong inducers
of Th-1 immune responses, and this
immunomodulatory effect may lead to
hypersensitivity reactions, instead of ben-
eficial effects. It is shown that a new subset
of lymphocytes (Th17) is triggered by
BCG, which induces the production of
pro-inflammatory cytokine (IL-17), which
is considered responsible for several auto-
immune diseases including asthma, hyper-
sensitivity pneumonitis, allergic airway
inflammation, diabetes mellitus, etc. [13].
Another NTM, M. avium ss paratuberculosis
(MAP), is a well-established cause of
Johne’s disease in animals, but its direct
role in the etiology of Crohn’s diseases has
been opposed [14]. Most of these studies
have shown only an association, and the
disease is considered an immune-mediated
condition where some genes increase
susceptibility of the gut mucosa to bacte-
rial flora including the MAP. One such
gene is CARD15/NOD2 situated within the
IBD1 region of chromosome 16q12.
Greater discussion on this issue is out of
the scope of this article.
Diagnosis
The major reasons for under-diagnosis
of NTM in TB-endemic regions are lack of
awareness, limited laboratory facilities,
Box 1. Possible Factors for Under-reporting of NTM from
TB-Endemic Countries
N NTM infections are not reportable in any country.
N Awareness is lacking among treating physicians and microbiologists.
N Laboratory infrastructure is lacking for culture and identification of non-
tuberculous mycobacteria.
N High burden of TB and HIV attracts the bulk of the attention of the health care
system; governmental fiscal inputs toward the costs of these neglected
infections continue to be neglected.
N Standardized or accepted criteria to define NTM respiratory disease are lacking.
Box 2. Facts about Non-tuberculous Mycobacterial Disease
N AIDS patients are significantly more vulnerable to NTM infections due to severe
T cell immunodeficiency.
N Solid organ transplant patients, even though immunocompromised, are not at
as high a risk as their HIV-positive counterparts.
N Although some genetic and anatomical factors predispose to NTM, no proven
associations have been proven among geographical, occupational, or ethnic
factors and NTM infections.
N Anatomical abnormalities and other co-morbidities such as chronic obstructive
pulmonary disease (COPD), bronchiectasis, cystic fibrosis (CF), pneumoconiosis,
past history of TB, pulmonary alveolar proteinosis, and esophageal motility
disorders are well-established predisposing conditions.
N Disseminated NTM infections have been associated with specific genetic
syndromes such as mutations in interferon (IFN)-c, interleukin (IL)-12 synthesis,
and in response pathways and the nuclear factor-kB essential modulator
(NEMO).
N Conventional methods are not sufficiently sensitive to estimate prevalence and
incidence of NTM infections.
N Monoplex TB-specific PCR needs to be replaced by multiplex PCR systems on
relevant clinical samples along with blood and urine samples in tertiary-care
settings.
N Multiplex PCR primers have been designed to amplify genus-specific regions, M.
tuberculosis complex specific, M. avium complex specific, M fortuitum complex
specific, and species-specific gene targets, that can be performed in a single
tube.
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the DOTS programme, treatment of
pulmonary tuberculosis is started only on
the basis of sputum microscopy results,
which has an inherent possibility of
missing the NTM disease [15]. While
most of the laboratories in TB-endemic
countries are dependent only on smear
examination to make the diagnosis of
tuberculosis, experience shows that appli-
cation of newer diagnostic methods such
as rapid culture methods, multiplex PCRs,
DNA probes, and/or 16S rDNA sequenc-
ing methods is more rewarding [2]. In our
settings, we found NTM in 17.6% of the
suspected MDR-PTB cases and in 12.4%
of the suspected extra pulmonary tuber-
culosis cases when we applied molecular
methods [2,9]. Therefore, to obtain the
best results, it is recommended that in
addition to high-quality sample collection,
the cultures should be inoculated in both
liquid and solid egg-based media and
preferably incubated at different tempera-
tures (at 28uC, 37uC, and 45uC). The
Multiplex PCR developed in our setting
directly on clinical samples was highly
useful in detecting the single and/or co-
infections of M. avium and M. tuberculosis
[2]. Liquid cultures are also useful in the
isolation of NTM from blood samples of
AIDS patients. The conventional bio-
chemical and phenotypic methods are
tedious, less rewarding, and take a long
time to speciate the mycobacterial isolates.
The application of PCRs, DNA probes,
and/or DNA sequencing methods makes
the characterization of NTM species the
least ambiguous. Recently, excretory pro-
teins such as MPB64 and MPT63 have
shown potential for differentiating MTB
and NTM with high accuracy [16].
Therefore, it may be concluded that
multiplex PCR systems targeting multiple
genes such as 16S-rRNA, hsp-65, ESAT-
6, MAC, cfp-10, or the internal transcribed
spacer (ITS) region of 16–23 S rRNA
primers are highly precise, rapid, cost-
effective, and can be used directly on
clinical samples (Figure 1) [2].
Treatment
Most of the NTM except M. kansasii are
inherently resistant or partially susceptible
to the standard anti-tubercular drugs.
Nonetheless, the availability of newer
macrolides/azilides has drastically changed
this situation. The macrolides clarithromy-
cin and azithromycin have become the
cornerstones of therapy for MAC [6].
Hence the utility of in vitro drug suscepti-
bility testing for NTM is an important
laboratory support. We have recently
standardized the in vitro drug susceptibility
testing for most of the NTM isolates. Most
of the NTM we studied were susceptible to
Ofloxacin (98%) and ciprofloxacin (90%),
but M. mucogenicum was susceptible only to
Figure 1. Genus- and species-specific diagnoses can be accomplished by using various PCR systems. (A) Genus-specific hsp65 PCR.
From lane M–14 are 100 bp marker, M tuberculosis, M. terrae, M. scrofulaceum, M. fortuitum, M. duvalii, M. smegmatis, M. chelonae, M. celatum, M. bovis
(BCG), M. kansasii, M. bovis, M. flavescens, M. goodii, and M. avium, respectively. Note a 441 bp amplicon in all species. (B) TB complex-specific cfp32
PCR. From lane M–14 are 1,000 bp marker, M tuberculosis H37 Rv, M tuberculosis clinical isolates (3), M. bovis (BCG), M. bovis, M. scrofulaceum, M.
fortuitum, M. duvalii, M. smegmatis, M. chelonae, M. celatum, M. kansasii, and M. flavescens, respectively. Note a 786 bp amplicon in M. tuberculosis (3)
and M. bovis (2) species. (C) PCR amplification of 16–23 S-rRNA using genus-specific primers ITS-F and Mycom-2; Lane M, 100 bp Marker; Lanes 1, 4, 7,
and 8 are M. tuberculosis isolates (121 bp); Lanes 2, 3, 5, and 6 are MAC isolates (144 bp); Lanes 9 and 12 are negative controls; and Lanes 10 and 11
are M. fortuitum isolates (223 bp). Other species of mycobacteria also yield amplicons of variable size specific for each species (unpublished data). (D)
A multiplex PCR comprised of primers for Mycobacterium genus (targeting hsp65), M. tuberculosis (targeting cfp10), and M. avium complex (targeting
MAC) specific genes. Lane M is 100 bp marker, Lanes 1 and 4 show M. tuberculosis single species infection (441 bp and 191 bp bands), Lanes 2 and 5
show M. avium complex single infection (441 bp and 144 bp bands), while Lanes 3 and 6 show mixed infection of M. tuberculosis + M. avium complex
(3 bands of 441 bp, 191 bp, and 144 bp size). The last lane is negative control.
doi:10.1371/journal.pntd.0000615.g001
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testing should be done against amikacin,
clarithromycin, quinolones, sulfamethoxa-
zole, doxycycline, and imipenem. Linezolid
and tigecycline may also be active. Local-
ized disease, especially with difficult-to-
treat NTM, may benefit from surgical
resection usually with adjunctive antibiotic
coverage of the NTM. Other complications
of NTM infection need to be treated
symptomatically, including the use of
corticosteroids, if warranted.
Conclusion and the Way
Forward
Even though there is no significant
difference in the incidence, prevalence,
and distribution of clinically relevant
NTM among various geographical or
ethnic subsets of countries, lack of aware-
ness and limited laboratory facilities are
the underlying reasons for their underre-
porting in TB-endemic countries. Several
risk factors have now been identified, and
it is possible to minimize the NTM disease
in these vulnerable patients. For species-
specific identification, it is recommended
that networks of national and regional
laboratories be developed. The conven-
tional methods of speciation must be
discouraged due to their non-reproduc-
ibility and tediousness. Molecular methods
such as multiplex PCR protocols need to
be put in place. Recognition of NTM as
an ‘‘emerging pathogen’’ would perhaps
elevate the status of NTM for better
research funding. Also, development of
an animal model would accelerate our
understanding of NTM disease and their
pathogenesis (Box 3).
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Box 3. Summary and Conclusions
The infections due to non-tuberculous mycobacteria (NTM) are increasing
worldwide, detrimentally affecting both HIV seronegative and immunocompro-
mised individuals. Cases of non-tuberculous mycobacteria are reported mainly
from European countries and America, where tuberculosis is not endemic. In TB-
endemic regions such as Southeast Asia and sub-Saharan Africa, the occurrence
of NTM is under-reported. This article reviews the various possible hypotheses of
reportedly low incidence and prevalence of NTM in TB-endemic countries, and
the authors provide their own view point on this issue. The authors think that:
1. There is a lack of systemic reporting of non-tuberculous mycobacterial diseases
due to overlapping clinical manifestations of tuberculosis and NTM diseases.
2. There is a lack of proper infrastructure for the identification of non-tuberculous
mycobacteria in TB-endemic regions.
3. Because of the high burden of tuberculosis in these regions, the whole attention
of health care workers and government is directed toward TB.
4. There is no geographical area or country unfit for the survival and spread of
NTM.
5. The notion that some ethnic groups or races are inherently resistant to NTM
infection has not been scientifically proven.
6. There is sufficient evidence that non-specific cross-immunity is developed due
to latent tuberculosis against these less-virulent NTM.
7. There are no systemic regional surveys for evaluating the true prevalence of
NTM.
8. Empirical use of fluoroquinolones and anti-tubercular drugs in relatively
dysfunctional health care settings gives a false impression of a low incidence
of non-tubercular cases.
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